Tag: AllianceBernstein

Intel Subject of Lawsuit Over Risky Hedge Fund Investments

The internal pension fund manager at Intel Corporation breached its fiduciary responsibility by investing in “risky and high-cost” hedge funds, a former Intel employee is charging in a lawsuit. The legal challenge comes as earlier this year Intel hired AllianceBernstein to […]

CLO Rule Change Clouds Outlook for Bank Loans

CLO Rule Change Clouds Outlook for Bank Loans

CLO Rule Change Clouds Outlook for Bank Loans by Gershon Distenfeld, AllianceBernstein  Retail investors fell out of love with US bank loans this year, but demand from issuers of collateralized loan obligations (CLOs) has remained strong. New regulations may change that. […]

In Energy Revolution, Bond Investors Must Keep Their Heads

In Energy Revolution, Bond Investors Must Keep Their Heads

In Energy Revolution, Bond Investors Must Keep Their Heads By Ivan Rudolph-Shabinsky  and Petter Stensland, Alliance Bernstein A surge in capital expenditures and leverage in the energy industry could end badly for some companies and their creditors. While select opportunities exist, we […]

Tinkering with The Core Bond Recipe

Tinkering with The Core Bond Recipe

Tinkering with The Core Bond Recipe via Alliance Bernstein This is the time of year when, in almost every American household, the tinkerer in the family eyes the recipe box. Certain venerable traditions will make it to the Thanksgiving table […]

China’s Property Market: The Risks for Banks

China’s Property Market: The Risks for Banks

China’s Property Market: The Risks for Banks By Hayden Briscoe (pictured) and Hua Cheng of AllianceBernstein (NYSE:AB) Despite worries about a collapse in China’s property market, we think the financial system will navigate the coming credit cycle if banks can buy time to resolve […]

Tax Inversions: Tail Wags Dog?

Tax Inversions: Tail Wags Dog? Posted by James T. Tierney, Jr. on Jun 19, 2014 in AllianceBernstein, Equities/Stocks The uproar over Pfizer’s (NYSE:PFE) failed bid for AstraZeneca (NYSE:AZN) has faded, but the tax inversion debate is just heating up. This week, Medtronic’s (NYSE:MDT) offer […]